The mechanism, efficacy and safety of Tofacitinib on the treatment of juvenile idiopathic arthritis
10.3760/cma.j.cn101070-20200925-01563
- VernacularTitle:托法替布治疗幼年特发性关节炎的机制、疗效及安全性研究
- Author:
Zhaoling WANG
1
;
Meiping LU
Author Information
1. 浙江大学医学院附属儿童医院风湿免疫过敏科，国家儿童健康与疾病临床医学研究中心，杭州 310052
- Keywords:
Juvenile idiopathic arthritis;
Janus kinase inhibitors;
Tofacitinib
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(7):556-558
- CountryChina
- Language:Chinese
-
Abstract:
Juvenile idiopathic arthritis(JIA) is one of the most common chronic connective tissue diseases characterized by unknown etiologic arthritis with the onset before the age of 16 years and disease course for more than 6 weeks.JIA may be accompanied by impairment of multiple organ function.Recent studies have shown the important role of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in the pathogenesis of JIA.Tofacitinib is an oral Janus kinase(JAK) inhibitor approved by Food and Drug Administration (FDA) in 2012 for the effective treatment of rheumatoid arthritis.However, there is little clinical evidence for the use of Tofacitinib in pediatrics.This review aims to clarify the mechanisms, efficacy and safety of Tofacitinib on the treatment of JIA.
